GLP-1 Market Monitor
$79.0bnAnnual market size
9.17%Forecast annual growth (CAGR)2025–2035
Active companies
Novo Nordisk
Other 🇩🇰, Denmark
Novo Nordisk develops and manufactures medicines for diabetes and obesity, including Ozempic and Wegovy (semaglutide). Its GLP-1 business includes injectable and oral formulations. This profile follows its product launches, commercial expansion and financial updates as it competes for patients and market share.
Market Cap
$189.3bn
As of 2026-09-14 · USD · Recorded monthly observations
Ticker Mentions
4
Last 12 months
Deal Activity
0
Last 12 months
What Is Happening at Novo Nordisk
- Oral obesity medicines continue to gain prescriptions
- Novo Nordisk launches the Wegovy pill in Germany
- Novo Nordisk raises its outlook after 7% adjusted sales growth
Mentioned In
Live Ticker
Novo Reports Greater Weight Loss Than a Tested Dose of Lilly’s Diabetes Drug
Novo Nordisk says its experimental CagriSema injection produced more weight loss than a tested dose of Lilly’s tirzepatide in adults with type 2 diabetes. The comparison does not cover every available dose.
Fierce Pharma Reports Record Weekly Prescriptions for Two Weight-Loss Pills
Fierce Pharma reported record weekly prescriptions for Novo’s Wegovy pill and Lilly’s Foundayo. The figures track prescriptions, including refills, rather than new patients or comparative treatment results.
Reuters Reports Wegovy Weight-Loss Pill Launch in Germany
Novo Nordisk has launched the daily tablet version of Wegovy in Germany, Reuters reported. The launch brings the weight-management medicine to its first European Union market in pill form.
Mentions:Novo Nordisk
Novo NordiskNovo Nordisk Raises Its Annual Sales Forecast
Novo Nordisk now expects a smaller decline in annual sales, citing improved expectations for diabetes and weight-loss medicines. The revised forecast still ranges from a 6% fall to no growth.
Mentions:Novo Nordisk
Novo Nordisk